Informed Investing
Subscribe
NewsArticlesLearnPodcastSubscribe

#Johnson & Johnson

NewsArticlesLearnPodcast
Johnson & Johnson vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? | The Motley Fool
OCTOBER 13, 2026

Johnson & Johnson vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? | The Motley Fool

Johnson & Johnson and Pfizer present distinct investment opportunities in the healthcare sector for 2026. J&J boasts robust sales from its Innovative Medicine and MedTech segments, with a projected revenue of up to $101.4 billion and a strong dividend history. In contrast, Pfizer focuses on biopharmaceuticals, facing challenges...

Read More >
Johnson & Johnson vs. Eli Lilly: Which Pharma Stock Can Make Your Portfolio Healthier in 2026? | The Motley Fool
OCTOBER 5, 2026

Johnson & Johnson vs. Eli Lilly: Which Pharma Stock Can Make Your Portfolio Healthier in 2026? | The Motley Fool

In the healthcare investment landscape for 2026, Johnson & Johnson (JNJ) offers stability with a diversified portfolio and strong operational efficiency, reporting $94 billion in revenue and a net income of $27 billion. Conversely, Eli Lilly (LLY) showcases rapid growth, achieving $65.2 billion in revenue, driven by blockbuster...

Read More >
Informed Investing
About UsContact
PrivacyTermsCopyright

Informed Investing is for informational and educational purposes only and is not financial, investment, tax, or legal advice. Nothing on this site constitutes a recommendation, solicitation, or offer to buy or sell any security or financial product. Investing involves risk, including loss of principal. Content may be developed with the assistance of analytical and automated tools, including AI systems, and is subject to human editorial review. Information may be incomplete, inaccurate, or outdated. You should independently verify information before acting on it and consult a qualified professional as appropriate.

© 2026 Informed Investing. All rights reserved.